Adagene to Present at Jefferies Global Healthcare Conference 2025
Adagene Inc. (Nasdaq: ADAG), a biotechnology company focused on antibody-based therapies, announced its participation in the Jefferies Global Healthcare Conference 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adagene Inc. (Nasdaq: ADAG), a biotechnology company focused on antibody-based therapies, announced its participation in the Jefferies Global Healthcare Conference 2025. Chief Strategy Officer Mickael Chane-Du will engage in one-on-one investor meetings and participate in a fireside chat on June 5, 2025, from 9:20-9:50 AM ET at the New York Marriott Marquis. The presentation will be available via webcast and accessible through the company's investor relations website for a minimum of 30 days.
Details
News Market Reaction – ADAG
The recorded move for ADAG in the trading session of this news was +4.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at the Jefferies Global Healthcare Conference 2025, taking place June 3-5 in New York, New York.
Jefferies Global Healthcare Conference 2025
- Fireside Chat Date: Thursday, June 5
- Fireside Chat Time: 9:20-9:50 AM (Eastern Time)
- Location: New York Marriott Marquis
- Webcast: https://wsw.com/webcast/jeff319/adag/1805752
A webcast of the presentation will be accessible in the Investors section of the company’s website at https://www.adagene.com for at least 30 days.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and Twitter.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor Contacts:
Raymond Tam
Adagene
raymond_tam@adagene.com
Bruce Mackle
LifeSci Advisors
bmackle@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.